Value
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 5.9 |
| P/S | 6.8 |
| EV/EBITDA | 3.2 |
| Fwd P/E | 7.9 |
| PEG | 3.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 15.4x
- ▸PEG: 4.15
NVS · Why this verdict
Why Novartis (NVS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Novartis delivers 35% ROE, 24% net margins, and a positive MACD breakout setup, but revenue declined 1% year-over-year, debt-to-equity is elevated at 1.2, the yield payout is flagged as unsafe, and consecutive earnings misses raise near-term execution concerns.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Novartis generates 35% ROE and 24% net margins, both exceptional for a large-cap pharmaceutical company, reflecting the pricing power and scale economics of its diversified global drug portfolio. Quality breakdown | Net margin remains above 20% and ROE stays above 25% for the next 4 reporting quarters, confirming the quality floor holds. | →Stable |
| CounterRevenue declined 1% year-over-year and the growth score is only 1.2/10, suggesting the margin profile is not being supported by volume growth and could compress as pricing power faces biosimilar competition. | ||
The data explicitly flags a leverage penalty from a debt-to-equity ratio of 1.2, which reduces the quality score and creates risk if interest rates remain elevated or if earnings disappoint and reduce debt coverage ratios. Bear case | Debt-to-equity ratio falls below 1.0 within 4 quarters as free cash flow is used for debt reduction. | →Stable |
| CounterA debt-to-equity of 1.2 is manageable for an investment-grade large-cap pharma with strong recurring cash flows, and the leverage may reflect strategic acquisitions that enhance the long-term pipeline rather than financial distress. | ||
The golden cross pattern, bullish MACD, and RSI of 51 in mid-range indicate a positive technical setup at a neutral momentum point, which has historically preceded continuation moves when combined with above-average fundamental quality. Momentum breakdown | Price rises above $160 within 6 months as the breakout pattern completes and institutional buyers respond to the technical setup. | →Stable |
| CounterOn-balance volume is falling, indicating that while price is above the 200-day moving average, actual buying pressure measured by volume accumulation is not confirming the breakout. | ||
Two consecutive earnings misses and a dividend payout flagged as high yield but unsafe indicate that both the earnings trajectory and the dividend sustainability are at risk, making income investors potentially exposed to a cut. Catalyst breakdown | Earnings surprise turns positive in at least 2 of the next 4 quarters, reducing the risk of a dividend cut. | →Stable |
| CounterAn average EPS surprise of negative 0.77% across 4 quarters is extremely close to consensus, suggesting the misses are rounding differences rather than fundamental execution problems. | ||
Novartis generates 35% ROE and 24% net margins, both exceptional for a large-cap pharmaceutical company, reflecting the pricing power and scale economics of its diversified global drug portfolio.
→StableQuality breakdown
- Expectation
- Net margin remains above 20% and ROE stays above 25% for the next 4 reporting quarters, confirming the quality floor holds.
CounterRevenue declined 1% year-over-year and the growth score is only 1.2/10, suggesting the margin profile is not being supported by volume growth and could compress as pricing power faces biosimilar competition.
The data explicitly flags a leverage penalty from a debt-to-equity ratio of 1.2, which reduces the quality score and creates risk if interest rates remain elevated or if earnings disappoint and reduce debt coverage ratios.
→StableBear case
- Expectation
- Debt-to-equity ratio falls below 1.0 within 4 quarters as free cash flow is used for debt reduction.
CounterA debt-to-equity of 1.2 is manageable for an investment-grade large-cap pharma with strong recurring cash flows, and the leverage may reflect strategic acquisitions that enhance the long-term pipeline rather than financial distress.
The golden cross pattern, bullish MACD, and RSI of 51 in mid-range indicate a positive technical setup at a neutral momentum point, which has historically preceded continuation moves when combined with above-average fundamental quality.
→StableMomentum breakdown
- Expectation
- Price rises above $160 within 6 months as the breakout pattern completes and institutional buyers respond to the technical setup.
CounterOn-balance volume is falling, indicating that while price is above the 200-day moving average, actual buying pressure measured by volume accumulation is not confirming the breakout.
Two consecutive earnings misses and a dividend payout flagged as high yield but unsafe indicate that both the earnings trajectory and the dividend sustainability are at risk, making income investors potentially exposed to a cut.
→StableCatalyst breakdown
- Expectation
- Earnings surprise turns positive in at least 2 of the next 4 quarters, reducing the risk of a dividend cut.
CounterAn average EPS surprise of negative 0.77% across 4 quarters is extremely close to consensus, suggesting the misses are rounding differences rather than fundamental execution problems.
Per-dimension breakdown
Quality
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 7.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 3.4 |
| FCF quality | 6.4 |
| Moat | 5.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Excellent ROE: 35%
- ▸Strong margins: 24%
- ▸Rule of 40: 21 (fail)
Growth
1.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.3 |
| EPS growth | 0.1 |
- ▸Declining revenue: -1%
Momentum
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.1 |
| Analyst rating | 5.0 |
| Price target | 5.0 |
- ▸LLM news sentiment: +0.43 (n=3)
Insider
5.0/10data confidence 50%Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 6.4 |
| growth rank | 1.3 |
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.6 |
| support resistance | 0.7 |
| 52w position | 8.4 |
Risk (lower is worse)
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.9 |
| days to cover | 7.2 |
| volatility | 7.9 |
| put call | 10.0 |
| implied vol | 7.5 |
| max pain risk | 7.0 |
| beta | 10.0 |
| debt equity | 4.6 |
Catalyst
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 2.6 |
| dividend safety | 4.2 |
| news activity | 7.0 |
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:5.0>=4.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:26d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.7=NEGATIVE
Warning (1)
- MOMENTUM:5.0<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-1.71
Upside
-13.1%
Downside
7.7%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 60, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Risk (lower is worse) at 8.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-1.7=NEGATIVE) reinforce the read. Current asymmetry R:R is -1.71 — supplementary context, not the trigger for this path.
The strongest dimensions are Risk (lower is worse) at 8.0, Quality at 7.0, and Sentiment at 5.7; the weakest are Growth at 1.2, Technical at 3.6, and Peer rank at 3.9. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.71 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Novartis generates 35% ROE and 24% net margins, both exceptional for a large-cap pharmaceutical company, reflecting the pricing power and scale economics of its diversified global drug portfolio.
Trip ifNet margin falls below 18% for 2 consecutive quarters.
- P2The data explicitly flags a leverage penalty from a debt-to-equity ratio of 1.2, which reduces the quality score and creates risk if interest rates remain elevated or if earnings disappoint and reduce debt coverage ratios.
Trip ifDebt-to-equity ratio rises above 1.5 in any reported quarter.
- P3The golden cross pattern, bullish MACD, and RSI of 51 in mid-range indicate a positive technical setup at a neutral momentum point, which has historically preceded continuation moves when combined with above-average fundamental quality.
Trip ifPrice falls below the 200-day moving average and remains below for more than 20 trading days.
- P4Two consecutive earnings misses and a dividend payout flagged as high yield but unsafe indicate that both the earnings trajectory and the dividend sustainability are at risk, making income investors potentially exposed to a cut.
Trip ifEPS surprise falls below negative 5% in at least 3 of the next 4 quarters, or a dividend cut of more than 20% is announced.